ClinicOps
Denmark market access · EU aligned

Enter the Danish market with the right evidence, language and accountable owners.

ClinicOps is Danish-led and gives international manufacturers, authorised representatives, research teams and localisation partners a controlled path into Denmark that stays aligned with the wider EU framework.

What the service does

Authority & requirement map

Identify the Danish and EU authorities, public primary sources, registrations, language surfaces and review owners relevant to the declared product or workflow.

Controlled Danish localisation

Map approved English/source content to Danish derivative content, preserve terminology and version provenance, route questions to the qualified owner and document closure.

Evidence reconciliation

Compare declared controlled sources with EUDAMED, regulatory master data, IFU/labelling, SS(C)P, study or operational records placed in scope.

Partner handoff

Route unresolved legal, regulatory, clinical, safety or specialist questions to the right client owner, or to an independent subject-matter expert whose credentials are checked for that engagement. Nothing is guessed.

Denmark first, Europe connected

Danish market question
Primary authority map
Approved source set
Danish/EU evidence reconciliation
Human-owned closure

The Danish Medicines Agency administers medical-device legislation in Denmark and works within the EU MDR/IVDR framework. For medicinal clinical trials in Denmark, the Danish Medicines Agency and ethics committees collaborate through the CTR/CTIS pathway. Where work touches healthcare delivery, authorisation or treatment-place governance, the Danish Patient Safety Authority becomes relevant. Which authorities are in scope is decided per engagement, not assumed.

Primary Danish authorities used in scope

Connected EU layer

MDR/IVDR & EUDAMED

EU medical-device rules, MDCG guidance and EUDAMED lifecycle data.

CTR / CTIS & GCP

European trial authorisation and ICH-GCP evidence context where a Danish-market question touches trial documents.

AI / EHDS / digital health

EU AI governance and health-data frameworks where they apply to the declared clinical workflow.

Language is controlled evidence, not a side service

ClinicOps treats translation and localisation as part of change control: approved source, target-language version, terminology decisions, reviewer identity, unresolved questions, approval and version closure. ClinicOps coordinates English↔Danish work and specialist review, and never presents a reviewed translation as regulatory approval.

The same discipline covers pharmacovigilance. Global PV systems hit three Danish walls. The local medical journals that GVP Module VI (VI.B.1.1.2) expects marketing-authorisation holders to monitor are written in Danish. Danish-language case reports and narratives need medically literate handling inside statutory reporting timelines. And for DHPCs, the MAH supplies the Danish draft and the Danish Medicines Agency quality-assures it before distributing it. ClinicOps provides that capacity as controlled evidence work — source, target, terminology decision, reviewer, closure — while qualified PV sign-off remains with the client’s safety organisation. No QPPV, deputy or national contact-person role is taken unless explicitly appointed.

Boundary. ClinicOps does not certify that a product, trial, clinic or document is legally compliant merely because a source was mapped or a translation was reviewed. The appropriate manufacturer, sponsor, healthcare, regulatory, legal or other qualified owner retains the reserved decision.

Qualified Danish pharmacovigilance capability

A medically trained, natively Danish safety-operations resource that works as an extension of your QPPV system — contract-ready for the 2026 rules. From 12 February 2026, Commission Implementing Regulation (EU) 2025/1466 requires every pharmacovigilance subcontract to set out roles and responsibilities, the method for exchanging safety data, and audit and inspection access, with no onward subcontracting without the MAH’s written consent, and makes risk-based audit of third parties mandatory (Regulation (EU) No 520/2012 as amended, Articles 6(3)–(4) and 13). ClinicOps is set up for exactly that: one named, auditable site your PSMF can list, with a trail your auditors can follow line by line.

Led by Ali Iskandar — Master of Science (MSc) in Medicine (Translational Medicine), Aalborg University — with hands-on pharmacovigilance experience and native Danish.

Medically trained, natively Danish

Master of Science (MSc) in Medicine (Translational Medicine), Aalborg University · ICH-GCP trained · native Danish, professional English · GVP-framework familiarity from operational pharmacovigilance practice. Danish safety work is language-bound: the national PV instruments (Lægemiddelloven and Executive Order 1191/2017) and the local medical literature exist only in Danish, and DHPCs reach Danish clinicians in Danish. Clinical reading and the language, in one reviewer.

Hands-on safety operations

ICSR case processing and MedDRA coding, and safety-database work (Argus, ArisG, EVWEB/EVDAS) in a specialist PV-provider setting — with medically informed English↔Danish case-narrative work. The everyday mechanics of a safety function, done to a controlled, reviewable standard.

Where the Danish need actually sits

Denmark does not mandate a local PV contact person: the Danish Medicines Agency states it will generally not request one, and EMA’s member-state register records that it has never been required of any MAH. You are paying for competence, not a statutory placeholder. The recurring work is Danish-language: journals that GVP Module VI expects you to monitor locally (titles such as Ugeskrift for Læger publish in Danish, outside the reach of a global English search); ICSR narratives and follow-up correspondence in Danish; and DHPCs, where the Danish draft is yours to supply and the Agency can return it if the translation falls short.

Governed, audit-ready method

Engagement terms drafted to Article 6(3): defined roles, a stated safety-data exchange method and timeline, audit and inspection access, no onward subcontracting without your written consent. Every Danish-language item logged with its first-awareness date and handed over on the agreed clock, with periodic reconciliation against your safety database. A justified journal list in writing. Version-controlled, terminology-consistent, human-reviewed — a record your QPPV, your sponsor and an inspector can each follow.

Scope of work (as appointed)

Danish local-literature monitoring with a justified journal list · ICSR and case-narrative language work · Danish DHPC drafts and safety-communication review to the Danish Medicines Agency’s plain-language expectations · Danish-language authority correspondence support · PV-document terminology and version control · controlled safety-information workflows. Scoped in writing to what you appoint — nothing assumed.

Inspect the method first, free and browser-local: Danish literature register · SDEA clause checker · Danish DHPC checker.

Scope Danish PV capacity →

Buyer and boundary

Buyer: marketing-authorisation holders, PV service providers and CROs covering Denmark from a global hub. Boundary: QPPV, deputy and national contact-person responsibilities are assumed only where explicitly appointed; medical assessment, causality and signal decisions stay with your safety organisation’s qualified reviewers. ClinicOps is the Danish-language operations layer — precise, accountable, and deliberately not the decision-maker.

Start with the market-access question